CheckMate 9LA PROs add support for first-line nivolumab–ipilimumab for advanced NSCLC
medwireNews: CheckMate 9LA trial findings indicate that a front-line nivolumab plus ipilimumab-based regimen slows the decline in health-related quality of life (HRQoL) for advanced non-small-cell lung cancer (NSCLC) patients compared with chemotherapy alone.
The patient-reported outcomes (PROs) were presented at the ESMO Virtual Congress 2020 by Martin Reck, from the LungClinic of Grosshansdorf in Germany, following on from the positive overall survival results he shared at the virtual 2020 ASCO Annual Meeting.
Reck described a “substantial delay” in the time to definitive deterioration from initiation of treatment for patients given the immunotherapy combination plus two cycles of chemotherapy versus those assigned to receive four cycles of chemotherapy alone (hazard ratio=0.66).
This significant benefit occurred across most of the Lung Cancer Symptom Scale (LCSS) symptoms, such as anorexia and fatigue, as well as the LCSS global index measures of distress, interference with activity and HRQoL.
Patients in both arms of the trial also experienced a trend towards improvement in the LCSS measures and the EQ-5D-3L visual analog scale for overall health status, although neither group met the minimal criteria for meaningful change in these outcomes.
medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2020 Springer Healthcare Ltd, part of the Springer Nature Group